Pharmacist-guided, patient-driven management of high blood pressure in CKD: A Novel Approach
Pharmacist-guided, patient-driven management of high blood pressure in CKD: A Novel Approach
批准号:
10535326
负责人:
Diana I Jalal
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-10-01 至 2026-09-30
关键词:
AddressAdherenceAffectAlbuminuriaAmbulatory CareAppointmentBlood PressureCardiovascular DiseasesCaringCharacteristicsChronic DiseaseChronic Kidney FailureCitiesClinic VisitsClinicalClinical PharmacistsClinical TrialsComplexConsolidated Framework for Implementation ResearchDataDialysis procedureDisease ProgressionEnd stage renal failureEvaluationExerciseFeasibility StudiesFundingGeneral PopulationGoalsHealth Care SurveysHealthcare SystemsHomeHome Blood Pressure MonitoringHypertensionInstructionInterventionInterviewIowaLearningMeasurementMethodsModalityModelingMonitorMorbidity - disease rateOutcomeOutpatientsParticipantPatientsPerformancePharmaceutical PreparationsPharmacistsPharmacy facilityPrevalenceProviderQuality of CareRandomizedReportingResearchResearch PersonnelRiskRisk FactorsSamplingSelf ManagementService delivery modelServicesStandardizationStructureSystemTestingTimeTitrationsUnited KingdomUnited States National Institutes of HealthUniversitiesVeteransVeterans Health Administrationarmbaseblood pressure controlblood pressure medicationblood pressure reductioncardiovascular disorder riskcardiovascular risk factorcare providerscare systemsdesignexperiencehealth care deliveryhealth care modelhigh riskhypertension controlimplementation evaluationimplementation facilitationimplementation frameworkimprovedinnovationmortalitymortality risknovelnovel strategiespatient engagementprimary outcomeprogramsshared decision makingstandard caretooltraditional care
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Background. Chronic kidney disease (CKD) associates with high morbidity and mortality due to CKD
progression and cardiovascular disease (CVD). Blood pressure (BP) lowering reduces the risk of CVD and
CKD progression. In spite of the large number of BP medications available, a significant proportion of Veterans
with CKD have BP above the goal. The current practice involves licensed providers performing medication
titrations to achieve BP goals and is associated with limited patient engagement. Our preliminary data indicate
that the implementation of pharmacist-guided patient-driven titration of BP medications is effective and feasible
in CKD. In this model, Veterans self-manage their BP medications under the guidance of the clinical
pharmacist based on a pre-determined medication titration plan.
Significance. The prevalence of CKD is extremely high among Veterans, with some studies reporting a
prevalence of 47% (vs 11% in the general population). Here, we propose a novel interdisciplinary care model
that engages the Veterans as an active participant in their care with the goal of improving BP control to
improve long term outcomes. The application addresses a key HSR&D priority (management of complex
chronic disease).
Innovation and Impact. First, the proposed care model is one that has not been tested and includes the
clinical pharmacist working with the provider and the Veterans so that Veterans with CKD can self-manage
their hypertension. While self-management is exercised in CKD once patients are on dialysis (via home
dialysis modalities), the self-management approach is not utilized in the earlier stages of CKD. Second, in the
approach, we will utilize a transdisciplinary approach to evaluate the implementation of pharmacist-guided self-
management of BP medications and we will apply constructs of an implementation science framework,
Consolidated Framework for Implementation Research (CFIR), to understand Veteran and system factors that
may either facilitate or impede the implementation and sustainment of the pharmacist-guided self-management
approach.
Specific aims. Specific aim 1 will evaluate if pharmacist-guided self-management of BP medications is more
effective than self-monitoring of home BP + the standard care amongst Veterans with CKD. Specific aim 2 will
identify and understand Veteran factors that may influence the acceptability of and the adherence to the self-
management approach whereas specific aim 3 will focus on understanding system factors that may facilitate or
impede the implementation of the self-management approach.
Methods. One hundred and sixty Veterans with uncontrolled hypertension and either stage 2 CKD with
albuminuria or stage 3 and 4 CKD will be randomized to either pharmacist-guided self-management or to self-
monitoring + the standard practice for 12 months. Aim 1 will evaluate change in [standardized] office systolic
BP at 12 months as the primary outcome. Aim 2 will utilize a mixed methods approach including semi-
structured interviews to evaluate a sample of 20 Veterans in each of the study arms. We will further design
data abstraction tools to evaluate the adherence to the intervention. In aim 3, we will utilize CFIR constructs to
guide our qualitative semi-structured interviews with key organizational stakeholders including PACT clinical
pharmacists, PCPs, and CKD providers (20 key stakeholders).
Implementation. The PI will implement the pharmacist-guided self-management approach with the Pharmacy
and Ambulatory care services as operational partners. The implementation of this approach will improve the
patient experience (Survey of Healthcare Experiences of Patients) and the quality of care
(Clinical Performance Measurement Program and the Strategic Analytics for Improvement and Learning).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Alternative Pathway of Complement: A Potential Contributor to Adverse Outcomes in CKD
-
批准号:10657133
-
项目类别:
-
资助金额:$62.94万
-
财政年份:2023
-
负责人:Diana I Jalal
-
依托单位:
Curcumin Supplementation for Improving Vascular and Cognitive Function
-
批准号:9754868
-
项目类别:
-
资助金额:$56.47万
-
财政年份:2017
-
负责人:Diana I Jalal
-
依托单位:
Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKD
-
批准号:8535735
-
项目类别:
-
资助金额:$17.94万
-
财政年份:2010
-
负责人:Diana I Jalal
-
依托单位:
Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKD
-
批准号:8137219
-
项目类别:
-
资助金额:$17.94万
-
财政年份:2010
-
负责人:Diana I Jalal
-
依托单位:
Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKD
-
批准号:8322797
-
项目类别:
-
资助金额:$17.94万
-
财政年份:2010
-
负责人:Diana I Jalal
-
依托单位:
Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKD
-
批准号:8720525
-
项目类别:
-
资助金额:$17.94万
-
财政年份:2010
-
负责人:Diana I Jalal
-
依托单位:
Is Uric Acid a Mediator of Endothelial Dysfunction in Patients with Chronic Kidne
-
批准号:7952507
-
项目类别:
-
资助金额:$17.94万
-
财政年份:2010
-
负责人:Diana I Jalal
-
依托单位:
海外基金